6 completed, 1 terminated. 5 Phase 1, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 4 | 2 | Completed 2 |
Follow TEPEZZA: new trials by email Literature Review of TEPEZZA trials Research Report on TEPEZZA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants Teprotumumab, Placebo - Healthy Volunteers | Phase 1 | Completed | Amgen | 20 | 2025-08-26 | 2026-02-27 |
| A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants Teprotumumab - Healthy Volunteers | Phase 1 | Completed | Amgen | 44 | 2023-03-24 | 2024-11-05 |
| A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease Teprotumumab - Thyroid Eye Disease | Phase 1 | Completed | Amgen | 16 | 2022-07-14 | 2024-06-21 |
| A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) TEPEZZA, Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 1 | Terminated | Amgen | 3 | 2021-11-17 | 2024-06-28 |
| TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study Teprotumumab, Placebo - Thyroid Eye Disease | Phase 4 | Completed | Amgen | 313 | 2021-09-16 | 2026-08-21 |
| A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease TEPEZZA, Placebo - Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease | Phase 4 | Completed | Amgen | 62 | 2021-09-02 | 2024-07-01 |
| A Study of TEPEZZA Subcutaneous Administration in Healthy Adults TEPEZZA, EDP - Bioavailability, Bioequivalence | Phase 1 | Completed | Amgen | 37 | 2020-09-22 | 2024-08-21 |
Graves Ophthalmopathy (6) · Bronchiolitis Obliterans Syndrome (1) · Exophthalmos (1) · Scleroderma, Diffuse (1) · Sedentary Behavior (1)
Amgen (7)
United States (6) · China (1) · France (1) · Germany (1) · Italy (1) · Spain (1) · United Kingdom (1)